Prothena halts birtamimab development after Phase 3 AFFIRM-AL trial fails to meet endpoints

In a major setback for Prothena Corporation plc, the company announced that its experimental therapeutic birtamimab failed to meet the primary or secondary endpoints in the Phase 3 AFFIRM-AL clinical trial targeting AL amyloidosis. The announcement marks a definitive halt to birtamimab’s development, including the discontinuation of the trial’s open-label extension. This decision arrives after an extensive and resource-intensive late-stage study involving 207 patients with Mayo Stage IV AL amyloidosis.

The Phase 3 AFFIRM-AL trial was designed as a global, double-blind, placebo-controlled study, focused on a high-risk group of treatment-naïve patients. Despite the rigorous clinical framework and inclusion of standard chemotherapy regimens such as bortezomib—with optional use of daratumumab—the investigational therapy failed to improve survival outcomes. The hazard ratio (HR) for all-cause mortality stood at 0.915 with a p-value of 0.7680, rendering the result statistically insignificant.

Prothena confirmed that neither of the key secondary endpoints—6-minute walk test distance and Short Form-36 Physical Component Score—showed clinical or statistical benefit. This outcome, although unexpected by the company, ultimately prompted a reevaluation of the asset’s commercial viability and scientific potential.

What Went Wrong with the AFFIRM-AL Trial?

Industry observers suggest that the complexity of AL amyloidosis, particularly in advanced Mayo Stage IV patients, might have played a critical role in limiting the therapeutic impact of birtamimab. While the drug was deemed generally safe and well-tolerated, its inability to alter mortality or improve patient function indicates potential shortcomings in its mechanism of action or patient stratification strategy.

Gene Kinney, Ph.D., President and CEO of Prothena, conveyed disappointment on behalf of the company and the wider patient community. His remarks reflected a sentiment often echoed in late-stage clinical trial failures—particularly in orphan diseases—where patient hope is deeply intertwined with therapeutic development. The company credited all participants, caregivers, and site investigators for their contribution to the trial.

How Will This Impact Prothena’s Financial and Organizational Strategy?

The collapse of birtamimab’s development will have far-reaching consequences for Prothena’s operational and financial roadmap. The company has already indicated a significant reduction in ongoing operating expenses, including a substantial downsizing of its workforce. A formal announcement detailing these plans is expected in June 2025.

Such restructuring measures are typical when a lead asset fails at a late-stage juncture, as companies need to rapidly reallocate capital to preserve long-term viability. Prothena’s upcoming evaluations with financial advisors suggest that strategic options—including potential partnerships, divestitures, or even M&A opportunities—may be explored to optimize shareholder value.

This development also underscores the high-stakes nature of biotech investing, where binary outcomes can drastically shift company trajectories and market sentiment within a short window.

What Remains in Prothena’s Clinical Pipeline?

Despite this setback, Prothena retains a diversified clinical pipeline focused on neurodegenerative and rare diseases tied to protein misfolding and amyloidosis. The company is pivoting its focus toward upcoming milestones, including data from the Phase 1 ASCENT clinical trial on PRX012, an experimental asset in Alzheimer’s disease. These initial results are anticipated by August 2025.

Further updates are also expected from key development partners. Roche is slated to provide mid-year progress on a partnered program, while Novo Nordisk has projected clinical updates for the second half of 2025. Bristol Myers Squibb is likewise expected to contribute new data from a partnered program in 2026. These collaborations suggest that despite the birtamimab failure, Prothena’s broader platform in protein dysregulation and neurological dysfunction retains industry interest and validation.

This portfolio includes candidates aimed at ATTR amyloidosis with cardiomyopathy, Parkinson’s disease, and other progressive neurodegenerative conditions. By balancing wholly-owned and partnered programs, the company aims to hedge pipeline risk while advancing treatments with significant unmet need.

How Does This Affect Investor Sentiment Toward Prothena Stock?

Following the announcement, investor sentiment toward Prothena Corporation plc has turned sharply negative, with the NASDAQ-listed stock witnessing downward pressure. While the trial result itself is a binary event, market reaction often extends to broader confidence in the company’s research methodology and its ability to extract clinical value from protein-targeted therapies.

In the near term, analysts are expected to revise their price targets, factoring in the discontinuation of birtamimab as well as potential cost savings from the restructuring plan. Institutional holders will also be closely evaluating management’s ability to deliver value through the remainder of its pipeline and partnerships.

In contrast, some long-term investors may interpret the pruning of birtamimab as a sign of disciplined capital deployment, potentially paving the way for more focused efforts in high-opportunity domains like Alzheimer’s and Parkinson’s.

What Are the Broader Implications for AL Amyloidosis Drug Development?

AL amyloidosis remains a complex and often underdiagnosed condition marked by the deposition of light-chain-derived amyloid fibrils in vital organs. Despite the entry of newer agents and improved diagnostic frameworks, treatment remains challenging—especially in advanced-stage patients.

Birtamimab’s failure highlights ongoing challenges in translating promising mechanisms into survival benefit, particularly in this patient population. It also adds to the growing list of setbacks that have historically hampered progress in rare amyloid diseases. The results may lead to a temporary chill in investor enthusiasm around this segment, especially for drugs not backed by robust biomarker-driven differentiation or combination potential.

That said, research into AL amyloidosis remains active, and lessons from Prothena’s trial may inform future designs—potentially prompting regulatory shifts toward more nuanced endpoints or adaptive trials.

What Comes Next for Prothena?

While the discontinuation of birtamimab is a significant blow, Prothena is not retreating from its mission. The next 12–18 months will be critical as the company unveils key data from ongoing studies and assesses its operational footprint. Strategic communication in June will provide additional visibility into cost management plans, while upcoming clinical milestones will determine the direction of investor confidence.

In a sector defined by volatility, scientific resilience, and investor scrutiny, Prothena’s ability to realign and refocus could serve as a test case in adaptive biotech management. The company’s willingness to exit non-viable programs and redirect resources may ultimately shape its long-term credibility in a hyper-competitive space where capital discipline is as important as innovation.